Genprex, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Genprex, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 1, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $0 | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
| FY2022 | Mar 31, 2021 | $0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 30, 2022 |
| FY2018 | Dec 31, 2018 | $0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.23M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($21.11M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($30.86M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($23.74M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($6.14M) | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | ($5.76M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($20.66M) | Mar 31, 2023 |
| FY2022 | Mar 31, 2021 | ($5.31M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.94M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($10.65M) | Mar 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.52M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($21.17M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($31.06M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($23.83M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($6.17M) | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | ($5.77M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($20.67M) | Mar 31, 2023 |
| FY2022 | Mar 31, 2021 | ($5.31M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.96M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($10.68M) | Mar 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.43M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $10.54M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $17.62M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $11.51M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $3.16M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $2.93M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $8.97M | Mar 31, 2023 |
| FY2022 | Mar 31, 2021 | $2.04M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $7.30M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.97M | Mar 26, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.31M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($17.92M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($24.74M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($17.62M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($14.28M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($13.94M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($6.92M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($6.85M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.17M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($1.25M) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $31.7K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $17.6K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $33.4K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $22.4K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.9K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.0K | Apr 17, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.16M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.12M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $10.67M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $25.09M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $29.95M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $34.57M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $39.41M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $42.86M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $31.37M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $3.53M | Mar 26, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.50M | Mar 30, 2026 |
| FY2022 | Sep 30, 2022 | $2.46M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $2.15M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $2.38M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $1.59M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.96M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.62M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $7.42M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $22.27M | Apr 1, 2025 |
| FY2022 | Sep 30, 2022 | $27.49M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $32.41M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $37.02M | Mar 31, 2023 |
| FY2023 | Dec 31, 2021 | $41.28M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $30.92M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $3.02M | Mar 30, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($171.03M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($154.80M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($133.69M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($102.83M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($96.30M) | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | ($90.16M) | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | ($84.40M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($79.09M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($58.42M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($40.48M) | Mar 26, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.60M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.74M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $20.95M | Apr 1, 2024 |
| FY2017 | Dec 31, 2017 | $161.3K | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | $1.60M | Apr 17, 2018 |
| FY2017 | Dec 31, 2015 | $234.2K | Apr 17, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (17) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (266) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (22) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | (19) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.29M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 217,234 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 1.49M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 1.20M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 47.87M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 43.12M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 19.26M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 15.24M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 11.72M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 11.36M | Apr 17, 2018 |